Patent estate

BTG International Inc. — Patent Portfolio

1 drug with active patents · 0 active patents · 0 expired · 1 biologic with BPCIA exclusivity

AI-enriched 0/0 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Patent estate by drug

Voraxaze (GLUCARPIDASE)

🧬 BPCIA biologic exclusivity to 2024-01-17

Sources

FDA Orange Book — small-molecule patents listed against approved NDAs.
FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
USPTO Patent Public Search — title, abstract, claim text grounding.
AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track BTG International Inc.'s patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export